BDTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 136524 min ago

@ $4.67

Išleistas: 14 vas. 2024 @ 20:53

Grąža: 4.28%

Ankstesnis signalas: vas. 13 - 22:50

Ankstesnis signalas: Pardavimas

Grąža: 11.73 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors...

Stats
Šios dienos apimtis	1.24M
Vidutinė apimtis	656 755
Rinkos kapitalizacija	273.95M
EPS	$0 ( 2024-05-14 )
Kita pelno data	( $-0.430 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.93
ATR14	$0.00800 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Campbell Shannon	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Raman Prakash	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Campbell Shannon	Buy	0
2024-04-10	Raman Prakash	Buy	0
2024-03-15	Behbahani Ali	Buy	3 166	Common Stock

INSIDER POWER
99.07
Last 97 transactions
Buy: 11 965 700 \| Sell: 275 000

Tūris Koreliacija

Ilgas: 0.14 (neutral)

Trumpas: 0.46 (neutral)

Signal:(40.518) Neutral

Black Diamond Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
APXI	0.912
SERA	0.895
BCSA	0.893
KINS	0.886
SLMBP	0.88
INBKZ	0.88
HYAC	0.88
TAYD	0.876
CRTO	0.876
BRAC	0.873

10 Labiausiai neigiamai susiję koreliacijos
RCON	-0.919
NUTX	-0.912
VRDN	-0.909
EGBN	-0.903
NFE	-0.9
GOVX	-0.899
PETS	-0.898
IMMX	-0.896
IMVT	-0.896
MNSB	-0.895

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Black Diamond Koreliacija - Valiuta/Žaliavos

-0.50
( neutral )

-0.64
( weak negative )

0.00
( neutral )

-0.41
( neutral )

-0.05
( neutral )

0.62
( weak )

Black Diamond Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2023
Pajamos:	$0
Bruto pelnas:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2022
Pajamos:	$0
Bruto pelnas:	$-3.24M (0.00 %)
EPS:	$-2.33

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.00347

Financial Reports:

No articles found.

Black Diamond Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Black Diamond

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.